A Hospital Based Survey on Lung Cancer Related-pain in Northern China

Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study

This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China.

Study Overview

• Status: Unknown
• Conditions: Lung Cancer; Cancer Pain

Detailed Description

Lung malignancies have become the most common cause of mortality among patients with cancer in China. A significant proportion of lung cancer patients suffer from cancer related pain, however few studies have reported the prevalence and clinical features of such pain, especially in China.

This study is a cross-sectional survey in 20 hospitals in Northern China. We designed two separate series of questions to be answered by patients and cancer management professionals. In the patient questionaire, we collect information on the prevalence, location, intensity, impact on life of lung cancer related pain. Questions on how doctors evaluate and manage the pain are included in both the patients' and physicians' surveys. In the doctors' questionaire, we also assess current situation of cancer pain educational programs attended in medical schools and post graduation through related questions.

• Study Type: Observational
• Enrollment (Anticipated): 2000

Contacts and Locations

• Study Contact: Name: Bo Zhang, MD; Phone Number: 86-10-87787447; Email: zh.bo@outlook.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

This is a cross-sectional study of clinical features (including prevalence, intensity and impact on life) of cancer-related pain in all lung cancer patients visiting the 20 participating hospitals in northern China on the designated day in July 2017. Meanwhile, all physicians receiving lung cancer patients in these hospitals are also enrolled to evaluate current management of lung cancer related pain in northern China. The patients will be identified in both outpatient clinics and inpatient wards of the involved hospitals. Informed consent will be obtained from participating patients and those who are not willing to provide pain information of interest and refuse to sign the ICF will be excluded.

Description

Inclusion Criteria:

1. The patient questionaire

   • All patients (outpatient and inpatient) diagnosed with lung cancer visiting the participating hospitals on the designated day of investigation
   • Informed consent must be obtained from the participating patients

2. The physician questionaire

   • All physicians who receive lung cancer patients (outpatient and inpatient) in the participating hospitals on the designated day of investigation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China	the proportion of self-reported pain related to cancer affecting the enrolled lung cancer patients over the past 24 hours	24 hours

Collaborators and Investigators

• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Collaborators: Peking University First Hospital; Shanxi Province Cancer Hospital; 307 Hospital of PLA; Peking Union Medical College Hospital; Chinese PLA General Hospital; Peking University Third Hospital; Henan Cancer Hospital; Peking University Cancer Hospital & Institute; Tianjin Medical University Cancer Institute and Hospital; Beijing Chao Yang Hospital; The First Affiliated Hospital of Zhengzhou University; Beijing Chest Hospital; Tianjin Medical University General Hospital; Hebei Medical University Fourth Hospital; 309th Hospital of Chinese People's Liberation Army; Inner Mongolia People's Hospital; The Hospital of Shunyi District Beijing; Daxing Hospital Beijing; Peking University Third Hospital Yanqing Hospital

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): June 1, 2017
• Primary Completion (ANTICIPATED): September 1, 2017
• Study Completion (ANTICIPATED): September 1, 2017

Study Registration Dates

• First Submitted: June 14, 2017
• First Submitted That Met QC Criteria: June 15, 2017
• First Posted (ACTUAL): June 16, 2017

Study Record Updates

• Last Update Posted (ACTUAL): June 16, 2017
• Last Update Submitted That Met QC Criteria: June 15, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Pain; Neurologic Manifestations; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Cancer Pain
• Other Study ID Numbers: CH-PT-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No